메뉴 건너뛰기
Blood
Volumn 117, Issue 12, 2011, Pages 3247-3248
Rethinking bioactivity of FLT3 inhibitors
Author keywords

[No Author keywords available]
Indexed keywords

CD135 ANTIGEN; LESTAURTINIB;
EID: 79953097953     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-02-334540     Document Type: Note
Times cited : (4)
References (6)
  • 1
    • 79953073247 scopus 로고    scopus 로고
    • FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
    • Sato T, Yang X, Knapper S, et al. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood. 2011;117(12):3286-3293.
    • (2011) Blood , vol.117 , Issue.12 , pp. 3286-3293
    • Sato, T.1    Yang, X.2    Knapper, S.3
  • 2
    • 79953124734 scopus 로고    scopus 로고
    • Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutantAMLin first relapse
    • Levis M, Ravandi F, Wang ES, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutantAMLin first relapse. Blood. 2011;117(12):3294-3301.
    • (2011) Blood , vol.117 , Issue.12 , pp. 3294-3301
    • Levis, M.1    Ravandi, F.2    Wang, E.S.3
  • 3
    • 0037114829 scopus 로고    scopus 로고
    • Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML study group Ulm
    • DOI 10.1182/blood-2002-05-1440
    • Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of theAMLStudy Group Ulm. Blood. 2002;100(13):4372-4380. (Pubitemid 35434129)
    • (2002) Blood , vol.100 , Issue.13 , pp. 4372-4380
    • Frohling, S.1    Schlenk, R.F.2    Breitruck, J.3    Benner, A.4    Kreitmeier, S.5    Tobis, K.6    Dohner, H.7    Dohner, K.8
  • 4
    • 0036659931 scopus 로고    scopus 로고
    • Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: Correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
    • DOI 10.1182/blood.V100.1.59
    • Schnittger S, Schoch C, Dugas M, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in theAMLCGstudy and usefulness as a marker for the detection of minimal residual disease. Blood. 2002; 100(1):59-66. (Pubitemid 35177429)
    • (2002) Blood , vol.100 , Issue.1 , pp. 59-66
    • Schnittger, S.1    Schoch, C.2    Dugas, M.3    Kern, W.4    Staib, P.5    Wuchter, C.6    Loffler, H.7    Sauerland, C.M.8    Serve, H.9    Buchner, T.10    Haferlach, T.11    Hiddemann, W.12
  • 5
    • 78650073854 scopus 로고    scopus 로고
    • FLT3 as a therapeutic target in AML: Still challenging after all these years
    • Kindler T, Lipka DB, Fischer T. FLT3 as a therapeutic target in AML: still challenging after all these years. Blood. 2010;116(24):5089-5102.
    • (2010) Blood , vol.116 , Issue.24 , pp. 5089-5102
    • Kindler, T.1    Lipka, D.B.2    Fischer, T.3
  • 6
    • 67650482985 scopus 로고    scopus 로고
    • In vitro enzymatic characterization of near full length EGFR in activated and inhibited states
    • Qiu C, Tarrant MK, Boronina T, et al. In vitro enzymatic characterization of near full length EGFR in activated and inhibited states. Biochemistry. 2009;48(28): 6624-6632.
    • (2009) Biochemistry , vol.48 , Issue.28 , pp. 6624-6632
    • Qiu, C.1    Tarrant, M.K.2    Boronina, T.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.